Category Archives: Co-infections

Health outcomes for clients of needle and syringe programs in prisons

2018

High levels of drug dependence have been observed in the prison population globally, and the sharing of injecting drug equipment in prisons has contributed to higher prevalence of bloodborne diseases...

Active case finding for communicable diseases in prison settings: Increasing testing coverage and uptake among the prison population in the European Union/European Economic Area

2018

Prison populations are disproportionally affected by communicable diseases when compared with the general community because of a complex mix of socioeconomic determinants and environmental factors. Tailored and adequate health care...

Chronic kidney disease in the global adult HIV-infected population: A systematic review and meta-analysis

2018

INTRODUCTION: The widespread use of antiretroviral therapies (ART) has increased life expectancy in HIV patients, predisposing them to chronic non-communicable diseases including Chronic Kidney Disease (CKD). We performed a systematic...

Linking private, for-profit providers to public sector services for HIV and tuberculosis co-infected patients: A systematic review

2018

BACKGROUND: Tuberculosis (TB) is the leading cause of infectious disease deaths worldwide and is the leading cause of death among people with HIV. The World Health Organization (WHO) has called...

Sexualised drug use in the United Kingdom (UK): A review of the literature

2018

BACKGROUND: Sexualised drug use (SDU) refers to the use of drugs in a sexual context. This includes ‘Chemsex’- the use of drugs (specifically crystal methamphetamine, GHB/GBL and mephedrone) before or...

Pharmacokinetics of efavirenz in patients on antituberculosis treatment in high HIV and tuberculosis burden countries: A systematic review

2017

AIMS: Efavirenz (EFV) and Rifampicin-Isoniazid (RH) are cornerstone drugs in HIV-tuberculosis (TB) co-infection treatment but with complex drug interactions, efficacy and safety challenges. We reviewed recent data on EFV and...

Approach to acute kidney injury in HIV-infected patients in South Africa

2017

Background: HIV-infected patients have an increased risk of renal disease. Current first-line antiretroviral therapy contains tenofovir disoproxil fumarate (TDF), which has nephrotoxic potential, characterised by proximal tubular cell injury. This...

Comorbidities and treatment outcomes in multidrug resistant tuberculosis: A systematic review and meta-analysis

2018

Little is known about the impact of comorbidities on multidrug resistant (MDR) and extensively drug resistant (XDR) tuberculosis (TB) treatment outcomes. We aimed to examine the effect of human immunodeficiency...

The effect of human immunodeficiency virus and cytomegalovirus infection on infant responses to vaccines: A review

2018

The success of prevention of mother to child transmission programs over the last two decades has led to an increasing number of infants who are exposed to human immunodeficiency virus...

Tuberculosis treatment outcomes in Ethiopia from 2003 to 2016, and impact of HIV co-infection and prior drug exposure: A systematic review and meta-analysis

2018

BACKGROUND: Knowledge of tuberculosis (TB) treatment outcomes is substantially needed to assess the performance of national TB controls programs (NTPs). To date, the overall estimates of treatment outcomes have not...

Sustained virological response in special populations with chronic hepatitis C using interferon-free treatments: A systematic review and meta-analysis of observational cohort studies

2018

BACKGROUND AND OBJECTIVES: Hepatitis C treatment has changed considerably in recent years, and many interferon (IFN)-free therapies are now available. Considering the high rates of sustained virological response (SVR) presented...

CD4 cell count threshold for cryptococcal antigen screening of HIV-infected individuals: A systematic review and meta-analysis

2018

Background: Current guidelines recommend screening all people living with human immunodeficiency virus (PLHIV) who have a CD4 count ≤100 cells/µL for cryptococcal antigen (CrAg) to identify those patients who could benefit...

Email 1 selected articles

Email 1 selected articles

Error! The email wasn't sent. Please try again.

Your email has been sent!